| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Taurocholic acid (Taurocholate; Cholyltaurine; N-Choloyltaurine) is a taurine conjugated bile acid produced endogenously from the conjugation of cholic acid with taurine. It can be used as a cholagogue and cholerectic.
| ln Vitro |
In isolated PBMCs from HBeAg-positive CHB patients, taurocholic acid (100 μM, 24 h) reduces the percentage of CD3+CD8+ T and NK cells[2]. IFN-α driven cytokine and cytotoxic granule levels (IFN-γ, TNF-α, granzyme B) in CD3+CD8+ T and NK cells are reduced by taurocholic acid (100 μM, 24 h)[2].
|
|---|---|
| ln Vivo |
When rAAV8-1.3HBV is injected into the tail vein of C57BL/6 mice, taurocholic acid (oral gavage, 100 mg/kg, 2 weeks) can increase HBV replication by decreasing the proportion of NK and CD3+CD8+ T cells [2]. By upregulating VEGF-A expression, taurocholic acid (1% in diet, 1 week) protects cholangiocyte injury caused by hepatic artery ligation (HAL) [3].
|
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice[2]
Doses: 100-mg/kg Route of Administration: po (oral gavage), for 2 weeks after tail vein injection with rAAV8-1.3HBV for 6 weeks Experimental Results: decreased the percentage of NK and CD3+CD8+ T cells . Increases serum HBsAg, HBeAg, and HBV DNA levels. |
| References |
[1]. Mooranian A, et al. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Deliv Transl Res. 2015 Oct;5(5):511-22.
[2]. Xun Z,et al. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function. Cell Mol Immunol. 2021 Feb;18(2):461-471. [3]. Glaser S, et al. Taurocholic acid prevents biliary damage induced by hepatic artery ligation in cholestatic rats. Dig Liver Dis. 2010 Oct;42(10):709-17. |
| Molecular Formula |
C₃₀H₅₃NO₇S
|
|---|---|
| Molecular Weight |
571.81
|
| CAS # |
81-24-3
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
C[C@H](CCC(NCCS(=O)(O)=O)=O)[C@@]1(C)CC[C@@]2(C)[C@]3(C)[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@]3(C)C[C@H](O)[C@]12C
|
| Synonyms |
Taurocholate CholyltaurineN-Choloyltaurine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~193.91 mM)
H2O : ~100 mg/mL (~193.91 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.85 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.85 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7488 mL | 8.7442 mL | 17.4883 mL | |
| 5 mM | 0.3498 mL | 1.7488 mL | 3.4977 mL | |
| 10 mM | 0.1749 mL | 0.8744 mL | 1.7488 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
